De betekenis van steroïdreceptoren voor de prognose en de hormonale behandeling van patiënten met mammacarcinoom: Een retrospectief onderzoek in Zuidoost-Nederland

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 31, 1998, Pages 1772-1778

  Voogd, A C ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NETHERLANDS; POSTMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; REGISTER; STANDARD; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NETHERLANDS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN;

EID: 0032129169     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McOuirc WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol lyβiX-.
2. Cooke T. George WO. Shields RD. Maynard P. Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet U)7u:i: WS-7-
3. Kinne l)W. Ashikari K. Butler A. Menende/-Botet C. Rosen PP. Schwärt/ M. Rstrogen receptor protein in hrcasl cancer as a predictor ol recurrence. Cancer 1X1:47:24-7.
4. Alanko A. Heinonen H. Scheinin IM. îolppancn LM. ihko K. Oestrogen and progesterone receptors and disease-tree interxal in primary breast cancer. BrJ Cancer iyS4:so:Mi7-72.
5. ollcnweider-Zerargui I.. Barrelet L. Wong . LcmarchandBeraud T. (iomey F. The predictive value ol estrogen and progesterone receptors' concentrations on the clinical behavior ol breast cancer in women. Clinical correlation on 447 patients. Cancer luSd:7:1171-So.
6. Collet) K. Harncit F. Skjaerven K. Machte HO. Prognostic role ol oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J Clin Pathol 1X1:4:20-. S
7. hek LI., Godolphin W. Surial with breast cancer: the importance of estrogen receptor quantity. F.ur J Cancer Clin Oncol iuSy:2:24ββo.
8. Raemaekers JM. Beex LV. Koenders A.I. Pieters (M . Smals A(i. Benraad TJ. el al. Disease tree interval and estrogen receptor acti ity in tumor tissue ol patients ith primary breast cancer: analysis alter long-term l'ollov-up. Breast Cancer Res Treat n)Kj;:h:i2j-βo.
9. Winstanley J. Cookc I. (ieorge WO. Murray (!. Holt S. ( roton R. et al. 1 he long term prognostic significance ol oestrogen receptor analysis in early carcinoma of the breast. BrJ Cancer Kw.(y:w-mi.
10. Raemaekers Jl. Bee LV. Pieters Gr. Snials AC.. Hcnraad I'J. Kloppenhorg P. Progesterone receptor activity and relapsc-lree survival in patients with primary breast cancer: the role oladjuant chemotherapy. Breast Cancer Res Treat iyS7:i.):iqi .
11. Hermanek P. Sobin LH. editors. U1CC INM classilication ol ma lignant tumours. Berlijn: Springer. 1X7:1.-7.
12. Andry (i. Suciu S. Pratola U. Sylvester R. Leclercq Ci. Da Costa PM. et al. Relationship between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance alter radical mastectomy lor primary breast cancer. Fur .1 Cancer Clin Oncol n)Sy:2β:βiy-2y.
13. Pichon MF. Broet P. Magdclenal H. Delarue .1C. Spyratos F. Hasuyau JP. et al. Prognostic value ol steroid receptors al'ter long-term follow-up ol us? oi'ierahle breast cancers. BrJ Cancer i i#ylS:7β: i s41.
14. Oe la Rochclordicrc A. Asselain B. ( ampana F. Scholl SM. Fenton .1. Vilcoq JR. et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet mmym:i(m)-_iβ.
15. ixon AJ. Xeuherg D. Haves DF. Oclman R. Connolly JL. Schnitt S. et al. Relationship of patient anc to pathologic features of the tumor and prognosis for patients ilh staue I or II breast cancer. J (lin Oncol iw:i2:SSX-y.
16. Bcc L AM. Peterse JL. Sortier JWR. Veelen 11 van. Hlankcnstcin MA. Receptoren oor steroïJhormonen en mammacareinoom. Ned Tijdschr Gcnccskd HMi:ih:2oβh-ho.
17. McClelland KA. Berger t". Miller LS. Powles 1.1. Coombes RC. Immunocytochemical assay for eslrogen icccptor in patients with breast cancer: relationship to a baxzhcmical assay and to outcome of therapy. J Clin Oncol iuSh:_):i 171-11.
18. Marchetti E. Ouer/oli P. Moneharmont B. Parikh I. Bagni A. Mar/ola A. et al. Immunoeytochemieal demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: eorre lation with cslroncn receptor assay b dextran-coated charcoal method. Cancer Res 1X7:47:20-iβ.
19. Holmes FA. Pritsche HA. Locwy JW, Geilner AM. Sutlon RC. Buzdar AU. el al. Measurement of cstrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol 1990:8:1025-35.
20. Fisher B. Redmond C. Brown A. Wickerham DL. Wolmark N. Allegra J. et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983:1:227-41.
21. Rose C. Thorpe SM. Andersen KW. Pedersen BV. Mouridsen HT. Blichert-Tol'l M. et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985:1:16-9.
22. Rutqvist LE. Cedermark B. Fomander T, Glas U. Johansson H. Nordenskjöld B. et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989:7:1474-84.
23. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992:11:117-20.
24. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998:351:1451-67.
25. Goldhirsch A. Wood WC, Senn HJ. Click JH, Gelber RD. Fifth International Conference on Adjuvant Therapy of Breast Cancer. St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 1995:3:1754-9.
26. McGuire WL. Tandon AK. Allred DC, Chamness'öc, Ravdin PM. Clark GM. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 1992:70(6 Suppl):i775-8i.
27. Mansour EG. Ravdin PM. Dressler L. Prognostic factors in early breast carcinoma. Cancer 1994:74(1 Suppl):38i-4OO.
28. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997:47:28-51.